Areas of focus

CrystalGenomics has been dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies, so as to address significant unmet medical needs in the areas of anti-infective, cancer, metabolic, and inflammatory diseases.

The company's lead developmental candidate in its novel product pipeline is a next generation NSAID, CG100649 with a mechanism of suppressing COX-2 as well as carbonic anhydrase for improved cardiovascular, gastrointestinal, and renal safety profile that has recently completed a phase IIa clinical trial in Europe with 248 osteoarthritis patients. Additionally, its novel HDAC inhibitor, CG200745, for cancer has successfully completed its IND-enabling toxicology studies in Europe and is anticipated for 1Q 2010 IND filing. The other novel antibiotics, CG400549 for MRSA and VRSA have just entered phase I study in Europe. This compound interrupts fatty acid synthesis process that is found in bacteria and seems to be an excellent drug candidate for the ‘superbugs'.

CrystalGenomics formed a consortium with Asan Medical Center for cancer research has established a US subsidiary called, CG Pharmaceuticals, for clinical development. The company has also established many drug discovery collaborations with leading pharmas and venture capital groups, including Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals and ProQuest Investments.